Read the Daily News for highlights from days 2 and 3 of the symposium.
Assessment of hearing loss associated with use of concurrent radiation and cisplatin delivered weekly versus every three weeks in patients with locally advanced head and neck cancers
Further Evidence that a Risk-Adapted Approach Yields Promise for Effective Treatment De-escalation
The combined positive score (CPS), which is defined as the number of PD-L1–staining cells (tumor cells, lymphocytes and macrophages) divided by the total number of viable tumor cells, multiplied by 100, is predictive of response to PD-1 blockade in the recurrent, metastatic setting. Robert Ferris, MD, and colleagues at the NRG, conducted a planned translational correlative study using biospecimens from NRG-HN003, which was a phase I study of definitive chemoradiotherapy and adjuvant pembroluzimab.
Investigators from the University of Michigan presented data from a phase II trial evaluating the utility of mid-treatment FDG-PET/CT to guide the use of de-intensified chemoradiotherapy.
Early Results of SAVER Phase I/II Trial for HPV-Related Oropharyngeal Cancer
Christina Henson, MD, and team reported consensus recommendations for radiographic imaging-detected extranodal extension in head and neck cancer, which is to harmonize and standardize the clinical practice and research.
For yesterday’s keynote, Ravindra Uppaluri, MD, PhD, Dana-Farber Cancer Center, Boston, spoke on the “Evolving Role of Neoadjuvant Immunotherapy in Curative-Intent Head and Neck Cancer.”
